Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Clinical Trial
Reports from Nevada Cancer Institute describe recent advances in breast cancer clinical trial
November 9th, 2008
New investigation results, 'Lapatinib and ixabepilone for the treatment of metastatic breast cancer,' are detailed in a study published in Pharmacotherapy. "Breast cancer is the second leading cause of cancer death in women. Treatment options for advanced-stage disease, although numerous, remain suboptimal," scientists in the United States report. "Lapatinib and ixabepilone are two new agents approved by the United States Food and Drug Administration (FDA) in 2007 for the treatment of locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). When added to the existing endocrine therapies-single--agent cytotoxic therapies and combination...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
